{"id":25849,"date":"2022-07-07T16:10:51","date_gmt":"2022-07-07T15:10:51","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=25849"},"modified":"2022-07-07T16:10:54","modified_gmt":"2022-07-07T15:10:54","slug":"fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/","title":{"rendered":"Fondation d&#8217;une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS"},"content":{"rendered":"\n<p>Article paru dans <a href=\"https:\/\/www.lesechos.fr\/industrie-services\/pharmacie-sante\/une-alliance-franco-allemande-pour-surmonter-la-resistance-aux-antibiotiques-1775024\" target=\"_blank\" rel=\"noreferrer noopener\">les Echos<\/a> le 07 juillet 2022<\/p>\n\n\n\n<p>BioM\u00e9rieux, poids lourd du diagnostic in vitro, et les laboratoires pharmaceutiques allemands Boehringer Ingelheim ainsi qu\u2019Evotec ont annonc\u00e9 hier fonder\u00a0une coentreprise pour contrer la r\u00e9sistance aux antibiotiques. <\/p>\n\n\n\n<p>\u00ab\u00a0<em>L\u2019antibior\u00e9sistance tue environ 1,27 million de personnes dans le monde chaque ann\u00e9e et on estime que, d\u2019ici \u00e0\u00a02050, on pourrait compter 10 millions de d\u00e9c\u00e8s en raison de l\u2019antibior\u00e9sistance, ce qui la rendrait plus mortelle que le cancer<\/em>\u00a0\u00bb, rappelle Michel Pairet, responsable innovation de Boehringer Ingelheim. <\/p>\n\n\n\n<p>Ce joint-venture (JV) \u2013 baptis\u00e9 \u00ab\u00a0Aurobac Therapeutics SAS\u00a0\u00bb \u2013 aura son si\u00e8ge \u00e0\u00a0Lyon, avec pour mission de cr\u00e9er la prochaine g\u00e9n\u00e9ration d\u2019antibiotiques ainsi que des solutions de tests afin d\u2019identifier l\u2019\u00e9ventuelle antibior\u00e9sistance d\u2019un patient et la surmonter.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Article paru dans les Echos le 07 juillet 2022 BioM\u00e9rieux, poids lourd du diagnostic in vitro, et les laboratoires pharmaceutiques allemands Boehringer Ingelheim ainsi qu\u2019Evotec ont annonc\u00e9 hier fonder\u00a0une coentreprise pour contrer la r\u00e9sistance aux antibiotiques. \u00ab\u00a0L\u2019antibior\u00e9sistance tue environ 1,27 million de personnes dans le monde chaque ann\u00e9e et on estime que, d\u2019ici \u00e0\u00a02050, on [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":25855,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Fondation d&#039;une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fondation d&#039;une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-07T15:10:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-07T15:10:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"679\" \/>\n\t<meta property=\"og:image:height\" content=\"453\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Fondation d&#8217;une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS\",\"datePublished\":\"2022-07-07T15:10:51+00:00\",\"dateModified\":\"2022-07-07T15:10:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\"},\"wordCount\":147,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\",\"name\":\"Fondation d'une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg\",\"datePublished\":\"2022-07-07T15:10:51+00:00\",\"dateModified\":\"2022-07-07T15:10:54+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg\",\"width\":679,\"height\":453,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Fondation d\u2019une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fondation d'une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/","og_locale":"fr_FR","og_type":"article","og_title":"Fondation d'une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2022-07-07T15:10:51+00:00","article_modified_time":"2022-07-07T15:10:54+00:00","og_image":[{"width":679,"height":453,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Fondation d&#8217;une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS","datePublished":"2022-07-07T15:10:51+00:00","dateModified":"2022-07-07T15:10:54+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/"},"wordCount":147,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/","name":"Fondation d'une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg","datePublished":"2022-07-07T15:10:51+00:00","dateModified":"2022-07-07T15:10:54+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/07\/Signature-business.jpg","width":679,"height":453,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/fondation-dune-une-coentreprise-pour-contrer-la-resistance-aux-antibiotiques-aurobac-therapeutics-sas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Fondation d\u2019une une coentreprise pour contrer la r\u00e9sistance aux antibiotiques, Aurobac Therapeutics SAS"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-23 05:20:39","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25849"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=25849"}],"version-history":[{"count":7,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25849\/revisions"}],"predecessor-version":[{"id":25867,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/25849\/revisions\/25867"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/25855"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=25849"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=25849"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=25849"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}